INNATE PHARMA : INNATE PHARMA (Euronext Paris: FR0010331421 - IPH) REPORTS
                     INCREASE IN ANNUAL REVENUE FOR 2012

  *Revenue of 14.3 million euros including payments from Bristol-Myers Squibb
    and research tax credit
  *Strong cash position with 32.6 million euros in cash, cash equivalents and
    current financial instruments as at December 31, 2012

                      (IFRS unaudited provisional data)

Innate Pharma SA  (Euronext Paris:  FR0010331421 - IPH),  the innate  immunity 
company developing first-in-class drugs for cancer and inflammatory  diseases, 
announces revenue and other  income of 14.3 million  euros for the year  2012, 
compared to 11.7 million euros in 2011.

The following table  breaks down the  operating revenue and  compares 2012  to 

                                   Fiscal year ended December 31,
In thousands of euros                                 2012   2011
Revenue from collaboration and licensing agreements 10,377  7,454
Government funding for research expenditures         3,898  4,286
Revenue and other income                            14,275 11,740

In 2012, revenue from  collaboration and licensing  agreements arose from  the 
agreement signed with  Bristol-Myers Squibb in  July 2011. Government  funding 
for research costs mostly represents research tax credit.

Cash,  cash  equivalents  and  current  financial  instruments  and  financial 

Cash, cash  equivalents  and  current financial  instruments  of  the  Company 
amounted to 32.6million euros at December 31, 2012.

At the same  date, the financial  liabilities of the  Company amounted to  4,5 
million  euros,  including  3.7  million  euros  related  to  the  twelve-year 
lease-financing agreement for the Company's  premises (until 2021) as well  as 
0.8 million euros related to Oséo^[1] reimbursable advances.

Full year results announcement:

Innate Pharma will  announce its full-year  results on March  5, 2013,  before 
market opening. Innate Pharma's management will host a conference call at  4pm 
CET. Dial-in details will be provided in the announcement press release.

About Innate Pharma:
Innate Pharma S.A.  is a biopharmaceutical  company developing  first-in-class 
immunotherapy drugs for cancer and inflammatory diseases.

The Company  specializes  in  the development  of  new  monoclonal  antibodies 
targeting receptors and pathways controlling the activation of innate immunity
cells. Its innovative approach has  been validated by licence agreements  with 
two major pharmaceutical companies, Novo Nordisk A/S and Bristol-Myers Squibb.

Incorporated in 1999  and listed  on NYSE-Euronext  in Paris  in 2006,  Innate 
Pharma is based in Marseilles, France, and had 82 employees as at December 31,

Learn more about Innate Pharma at

Practical Information about Innate Pharma shares:

ISIN code   FR0010331421
Ticker code IPH

This press release contains certain forward-looking statements. Although the
company believes its expectations are based on reasonable assumptions, these
forward-looking statements are subject to numerous risks and uncertainties,
which could cause actual results to differ materially from those anticipated.
For a discussion of risks and uncertainties which could cause the company's
actual results, financial condition, performance or achievements to differ
from those contained in the forward-looking statements, please refer to the
Risk Factors ("Facteurs de Risque") section of the Document de Reference
prospectus filed with the AMF, which is available on the AMF website
( or on Innate Pharma's website (

This press release and the information  contained herein do not constitute  an 
offer to sell or a solicitation of an  offer to buy or subscribe to shares  in 
Innate Pharma in any country.

For additional information, please contact:

Innate Pharma
Laure-Hélène Mercier
Director, Investor Relations
Tel.: +33 (0)4 30 30 30 87

ATCG Press
Marielle Bricman
Mob.: +33 (0)6 26 94 18 53

[1]Oséo is a public-sector institution dedicated to economic development



This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
information contained therein.

Source: INNATE PHARMA via Thomson Reuters ONE
Press spacebar to pause and continue. Press esc to stop.